Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Quadrupling Inhaled Glucocorticoid Dose to Abort Asthma Exacerbations.

McKeever T, Mortimer K, Wilson A, Walker S, Brightling C, Skeggs A, Pavord I, Price D, Duley L, Thomas M, Bradshaw L, Higgins B, Haydock R, Mitchell E, Devereux G, Harrison T.

N Engl J Med. 2018 Mar 8;378(10):902-910. doi: 10.1056/NEJMoa1714257. Epub 2018 Mar 3.

2.

FourFold Asthma Study (FAST): a study protocol for a randomised controlled trial evaluating the clinical cost-effectiveness of temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations.

Skeggs A, McKeever T, Duley L, Mitchell E, Bradshaw L, Mortimer K, Walker S, Parrott S, Wilson A, Pavord I, Brightling C, Thomas M, Price D, Devereux G, Higgins B, Harrison T, Haydock R.

Trials. 2016 Oct 13;17(1):499.

3.

Effects of the BDNF Val66Met polymorphism and met allele load on declarative memory related neural networks.

Dodds CM, Henson RN, Suckling J, Miskowiak KW, Ooi C, Tait R, Soltesz F, Lawrence P, Bentley G, Maltby K, Skeggs A, Miller SR, McHugh S, Bullmore ET, Nathan PJ.

PLoS One. 2013 Nov 11;8(11):e74133. doi: 10.1371/journal.pone.0074133. eCollection 2013.

4.

Neural and behavioral effects of a novel mu opioid receptor antagonist in binge-eating obese people.

Cambridge VC, Ziauddeen H, Nathan PJ, Subramaniam N, Dodds C, Chamberlain SR, Koch A, Maltby K, Skeggs AL, Napolitano A, Farooqi IS, Bullmore ET, Fletcher PC.

Biol Psychiatry. 2013 May 1;73(9):887-94. doi: 10.1016/j.biopsych.2012.10.022. Epub 2012 Dec 14.

5.

Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects.

Ziauddeen H, Chamberlain SR, Nathan PJ, Koch A, Maltby K, Bush M, Tao WX, Napolitano A, Skeggs AL, Brooke AC, Cheke L, Clayton NS, Sadaf Farooqi I, O'Rahilly S, Waterworth D, Song K, Hosking L, Richards DB, Fletcher PC, Bullmore ET.

Mol Psychiatry. 2013 Dec;18(12):1287-93. doi: 10.1038/mp.2012.154. Epub 2012 Nov 13. Erratum in: Mol Psychiatry. 2014 Dec;19(12):1341.

6.

Multiple-dose safety, pharmacokinetics, and pharmacodynamics of the μ-opioid receptor inverse agonist GSK1521498.

Nathan PJ, Bush MA, Tao WX, Koch A, Davies KM, Maltby K, O'Neill BV, Napolitano A, Skeggs AL, Brooke AC, Richards DB, Williams PM, Bullmore ET.

J Clin Pharmacol. 2012 Oct;52(10):1456-67. Epub 2011 Dec 12.

PMID:
22162534
7.

Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel μ-opioid receptor inverse agonist.

Nathan PJ, O'Neill BV, Bush MA, Koch A, Tao WX, Maltby K, Napolitano A, Brooke AC, Skeggs AL, Herman CS, Larkin AL, Ignar DM, Richards DB, Williams PM, Bullmore ET.

J Clin Pharmacol. 2012 Apr;52(4):464-74. doi: 10.1177/0091270011399577. Epub 2011 May 24.

PMID:
21610207
8.

Distinct modulatory effects of satiety and sibutramine on brain responses to food images in humans: a double dissociation across hypothalamus, amygdala, and ventral striatum.

Fletcher PC, Napolitano A, Skeggs A, Miller SR, Delafont B, Cambridge VC, de Wit S, Nathan PJ, Brooke A, O'Rahilly S, Farooqi IS, Bullmore ET.

J Neurosci. 2010 Oct 27;30(43):14346-55. doi: 10.1523/JNEUROSCI.3323-10.2010.

Supplemental Content

Loading ...
Support Center